1. Home
  2. OEC vs DMAC Comparison

OEC vs DMAC Comparison

Compare OEC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orion S.A.

OEC

Orion S.A.

HOLD

Current Price

$7.15

Market Cap

397.0M

Sector

Industrials

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$6.32

Market Cap

381.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OEC
DMAC
Founded
1862
2000
Country
Luxembourg
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.0M
381.5M
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
OEC
DMAC
Price
$7.15
$6.32
Analyst Decision
Sell
Strong Buy
Analyst Count
4
4
Target Price
$6.56
$15.50
AVG Volume (30 Days)
708.2K
197.5K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
1.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,806,700,000.00
$500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.35
$4.01
52 Week High
$11.21
$10.42

Technical Indicators

Market Signals
Indicator
OEC
DMAC
Relative Strength Index (RSI) 51.85 40.30
Support Level $6.66 $6.45
Resistance Level $7.70 $6.54
Average True Range (ATR) 0.40 0.43
MACD 0.09 -0.15
Stochastic Oscillator 67.69 4.75

Price Performance

Historical Comparison
OEC
DMAC

About OEC Orion S.A.

Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical, and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. The Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing, and special applications. Geographically, it derives a majority of its revenue from Germany.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: